Poly Ethylene Glycol (PEG)-Related Controllable and Sustainable Antidiabetic Drug Delivery Systems

Yupeng Fu^a, Ying Ding^a, Litao Zhang^a, Yongmin Zhang^{a,b}, Jiang Liu^{a*}, Peng Yu^{a*}

^a China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, 300457 Tianjin, China

^b Sorbonne Université, CNRS, IPCM, UMR 8232, 4 Place Jussieu, 75005 Paris, France

* Corresponding authors e-mail address: liu.jiang@tust.edu.cn (Jiang Liu), yupeng@tust.edu.cn (Peng Yu)

ABSTRACT

Diabetes mellitus is one of the most challenging threats to global public health. To improve the therapy efficacy of antidiabetic drugs, numerous drug delivery systems have been developed. Polyethylene glycol (PEG) is a polymeric family sharing the same skeleton but with different molecular weights which is considered as a promising material for drug delivery. In the delivery of antidiabetic drugs, PEG captures much attention in the designing and preparation of sustainable and controllable release systems due to its unique features including hydrophilicity, biocompatibility and biodegradability. Due to the unique architecture, PEG molecules are also able to shelter delivery systems to decrease their immunogenicity and avoid undesirable enzymolysis. PEG has been applied in plenty of delivery systems such as micelles, vesicles, nanoparticles and hydrogels. In this review, we summarized several commonly used PEG-contained antidiabetic drug delivery systems and emphasized the advantages of stimuli-responsive function in these sustainable and controllable formations.

Keywords: PEG, drug delivery system, antidiabetic, stimulating responsive release, sustainable release

26
27
28
29
30
31
32
33
34
35

Content

1 Introduction 3

2 PEGylated micelles in antidiabetic treatments 9

3 PEGylated vesicles in antidiabetic treatments 15

4 PEGylated nanoparticles (NPs) in antidiabetic treatments 22

5 PEGylated hydrogels in antidiabetic treatments 27

6 Conclusion 33

Reference 36

1 Introduction

Diabetes mellitus is a severe chronic metabolic disease which imposes enormous burdens both personally and socially¹. It is estimated that 4 million people died of diabetes and its complications in 2017, which has caused vast economic losses². Generally, diabetes is classified into three subtypes: type 1 diabetes mellitus (T1DM) is an autoimmune disease, induced by the destruction of pancreatic β -cells which produce insulin³, type 2 diabetes mellitus (T2DM) is generated by the insufficient insulin supply or the insulin resistance⁴, gestational diabetes mellitus (GDM) is a glucose intolerance which first diagnosed during pregnancy⁵. Among all these subtypes, T2DM is the biggest threat to public health, the figure for T2DM patients almost accounting for 90% of the total⁶. A wide range of diabetes therapies including behavioral⁷, nutritional⁸, physical⁹ and the most important, medicamentous therapies, have been adopted to alleviate diabetes and its complications.

Drug delivery systems (DDSs) plays a vital role in the clinical application of antidiabetic treatments since many antidiabetic drugs cannot achieve the ideal therapeutic effect without any assistance from a delivery system. Thus, appropriate DDSs are crucial in the designing of formulations. PEG-contained delivery systems are regarded as ideal options for the optimization of antidiabetic drug deliveries. PEG is a family of amphiphilic polymers¹⁰ that sharing the same skeleton of repeating ethylene glycol units $[(CH_2CH_2O)_n]$ but with different molecular weights¹¹. The most commonly used PEGylated reagents are the linear types of PEG chains. Except for the linear type, various shapes of PEG derivatives had been developed to meet different functions of specific attempts (**figure 1**). The derivation of PEG allowed more functionalization sites to be accessed, that broken through the limitations of the linear type PEG¹², however, the derivation of PEG brought chemistry challenges in synthesis compared to the linear type PEG. Generally, PEGs have been extensively used in DDSs to ameliorate the physiochemical properties and bioactivity of various substrates¹³.

Figure 1. PEG and multiple derivatives obtained via different linking methods such as linear (A), 3-arm (B), 4-arm (C), Y-shaped (D) and comb-like polymers (E)¹⁴.

PEG molecules consisting of the DDSs are able to shield DDSs and drugs by their long hydrophilic chains. This distinctive architecture generally renders the delivery particles four characters: 1) enhanced enzymatic stability; 2) expanded hydrodynamic volume; 3) reduced immunogenicity of the large biomolecules and 4) decreased possibility of the macromolecules aggregation. These properties can decrease the kidney clearance, prolong the internal lifespan and promote the stability of particles, which lead to improved therapeutic effects¹⁵. Owing to its unique structure, PEG endows natural or artificial materials with improved physiochemical properties and biodegradability¹⁶.

Besides, due to the absence of inherent bioactivity, antidiabetic PEGylated polymeric systems can provide optimization of delivery and release process *in vivo* such as the prolonged half-life time¹⁷. Diverse types of PEGylated antidiabetic DDSs including nanoparticles, microspheres, nanovesicles, micelles and hydrogels are able to fit novel administration of drugs like transdermal¹⁸ and oral administration¹⁹ of insulin and intelligent insulin injections²⁰ which are able to overcome the disadvantages of traditional open-loop insulin delivery systems²¹. A number of studies have verified the advantages of PEGylated DDSs in diabetes treatments (table 1).

Table 1. Part of the PEGylated DDSs applied in antidiabetic treatment

Loaded drug	DDS	Antidiabetic activity investigation model	Route of administration	Features
Insulin ²²	mPEG- <i>b</i> -P(GA- <i>co</i> -GPBA) micelles	Not applicable (N/A)	N/A	Glucose-responsive insulin release <i>in vitro</i>

Insulin ²³	PEG-PE micelles	BALB/c male mice	Intraperitoneal (i.p.) injection	Promote the renaturation of DTT-induced aggregated insulin
Insulin ²⁴	PEG/PNIPAM-P (Asp- <i>co</i> -AspPBA)/P (Asp- <i>co</i> -AspGA- <i>co</i> -AspNTA) complex micelles	STZ-induced mice	Subcutaneous (s.c.) injection	Protease resistance, improved blood glucose regulation capacity
Insulin ²⁵	PEG- <i>b</i> -P(AA- <i>co</i> -APBA)/P(AA- <i>co</i> -AGA) micelles	N/A	N/A	Enhanced glucose-responsive capacity
Insulin ²⁶	Microsphere loaded with CA-PLGA- <i>b</i> -(PEI-PEG) micelles-insulin conjugates	STZ-induced rats	S.c. injection	Reduced cytotoxicity, extended efficacy time
Insulin ²⁷	Insulin-deoxycholate composite micelles encapsulated by PCL-PEG-PCL vesicles	STZ-induced rats	S.c. injection	Improved encapsulation efficiency
Insulin ²⁸	PEG-P (Ser-ketal) nanovesicles	STZ-induced mice	S.c. injection	Acid-responsive insulin release <i>in vivo</i> with extended blood glucose regulation time
Insulin ¹⁸	Microneedle array loaded with mPEG- <i>b</i> -P(SerPBE) vesicles	STZ-induced mice	Transdermal administration	Painless administration with glucose-responsive insulin release
Insulin ²⁹	Microneedle array loaded with PEG-poly (Ser-S-NI) vesicles	STZ-induced mice	Transdermal administration	Enhanced and stable blood glucose regulation ability with low hypoglycemia risk
Insulin ³⁰	DSPE-PEG-coated DPPC liposomes	STZ-induced rats	Femoral venous cannula	Improved incorporation efficiency and stability, more uniform particle size
Insulin ³¹	PEG-PLGA nanoparticles	STZ-induced mice	S.c. injection	Sustain therapeutic effect with same minimum blood glucose level compared with free insulin
Insulin ³²	TPGS-emulsified PEG-capped-PLGA nanoparticles	STZ-induced rats	Oral administration	Oral administration validity of insulin, prolonged plasma glucose regulation time
Exenatide ³³	IgG Fc modified exenatide loaded by PEG-PLGA nanoparticles	Db/db mice	Oral administration	Obvious hypoglycemic effect compared with oral administration and SC injection of exenatide solution
Insulin ³⁴	Zn-insulin conjugates loaded by PLGA-PEG nanoparticles	N/A	N/A	Enhanced entrapment capacity with small particle size, sufficient stability for long-term storage
Insulin ³⁵	HP-55-coated capsules loaded with microparticles containing PLGA-lipid-PEG nanoparticles	STZ-induced rats	Oral administration	Oral administration validity of insulin, improved cell uptake, extended efficacy time with stable hypoglycemic effect
Plasmid DNA encoding GLP-1 ³⁶	Linear PEI/plasmid DNA nanoparticles coated by DPPC/1,2-dimyristoyl- <i>rac</i> -glycero-3-methoxy PEG-2000 (DMG-PEG)	Balb/c mice and db/db mice	Oral administration	Obvious blood glucose regulation induced by highly expressed GLP-1 gene transfected by NPs

Exenatide ³⁷	PEG- <i>b</i> -(PELG ₅₀ - <i>g</i> -PLL ₃) nanoparticles	STZ-induced rats	S.c. injection	Prolonged plasma duration time and hypoglycemic effect
Exenatide ³⁸	Zn-exenatide conjugates loaded by PEG-PLGA nanoparticles with low molecular weight protamine as oral absorption promoter	SD rats and db/db mice	Oral administration	Oral administration validity, extended efficacy time, higher plasma maximum concentration, enlarged AUC (3.27 folds), enhanced bioavailability compared with s.c. administration
Repaglinide ³⁹	PEG-PLGA nanoparticles	STZ-induced rats	Oral administration	Extended efficacy time
Insulin ¹⁹	Calcium phosphate-PEG-insulin-casein particles	Female non-obese diabetic mice	Oral administration	Oral administration validity
Insulin ⁴⁰	Zn-insulin complexes loaded by PLA-PEG-PLA thermogel	STZ-induced SD rats	S.c. injection	Extended blood glucose regulation time, stable and prolonged plasma insulin concentration
Liraglutide ⁴¹	PCGA-PEG-PCGA hydrogel	ICR mice and db/db mice	S.c. injection	Extended efficacy time
Lixisenatide ⁴²	PLGA-PEG-PLGA/PCGA-PEG-PCGA mixture hydrogel	ICR mice and SD rats	S.c. injection	Prolonged plasma lifespan, extended blood glucose regulation time, 7.6 folds larger AUC
Exenatide ⁴³	Depot-gel-in-microsphere-in-Matrix-gel system	SD rats	S.c. injection	Significant prolonged release time (46 days) with retained blood glucose regulation activity
Insulin ⁴⁴	4-arm-PEG acrylic hydrogel	N/A	N/A	Sensitive glucose-induced oxidation-degradation to achieve sustainable insulin release
Insulin ⁴⁵	Semi-IPN chitosan-PEG-pAAm hydrogel	N/A	N/A	Sensitive glucose-responsiveness, improved swelling ratio, drug loading capacity and entrapment efficiency derived from the increased PEG ratio
Insulin ⁴⁶	Arg-PEA/PEG-DA hybrid hydrogel with TD-1 as transdermal promoter	STZ-induced ICR mice	Transdermal administration	Good biocompatibility, moderate and prolonged blood glucose regulation capacity

As table 1 displayed, plenty of cases confirm the advantages of PEG as the ingredient of delivery systems. Among these fascinating systems, micelles, vesicles, nanoparticles (NPs), hydrogels and microneedles captured much attention due to their intrinsic properties. For example, micelles and vesicles

are able to encapsulate drugs, including but not limited to small-molecule drugs, peptides, proteins, DNA, with high efficiency to achieve efficient administration⁴⁷. Microneedles array is considered as an effective transdermal administration of insulin since its painless, low cost and convenient for self-administration⁴⁸. Pharmacokinetically, transdermal administration like microneedles matrix is able to bypass the “first-pass” elimination and the reduced maximum blood drug concentration also could minimize the risk of side effects⁴⁹.

In recent decades, long-acting formulations with stable and controllable drug release profile are gaining much attention. These “intelligent” formulations generally require an adjustable release process to get with the physiological or pathological changes (like blood glucose concentration fluctuation, temperature variation or oxidative conversion of circumstance) to achieve the optimal dosage distribution in the whole release process. For instance, a severe side effect of conventional insulin injections is the excessive hypoglycemia induced by the burst release of insulin in the blood, the efficacy time is also restricted. By contrast, the release profile of intelligent DDSs is more moderate and persistent. Thus, the responsiveness to physiological or pathological changes, in the other words, the stimuli-responsive capacity is one of the crucial features for sustain release formulations.

Specifically, glucose-responsive capacity, which is able to inhibit the burst release of drugs to prevent undesirable hypoglycemia events and prolong the plasma glucose regulation time, is important for intelligent formulations in antidiabetic treatments. The glucose-responsive capacity of PEG-based DDSs can be achieved by introducing glucose-sensitive functions. For example, phenylboronic acid (PBA) is able to endow PEG-based DDSs with glucose-responsive capacity. As **scheme 1** demonstrated, there are two forms of PBA compounds in aqueous milieu⁵⁰: uncharged/relatively hydrophobic form and charged/relatively hydrophilic form. Since charged borate is capable of covalently forming a stable hydrophilic complex with glucose through the esterification between boronic acid and *cis*-diol group. This reaction induces the hydrophilic conversion of PBA-contained components in aqueous milieu (like blood),

leading to the degradation of PBA-based micelles and the release of insulin loaded by micelles.

Scheme 1. The reversible formation of PBA-glucose complex

The earliest report of the reaction between glucose and PBA was reported by Kuivila, Henry G. *et al.*⁵¹. As time goes by, plenty of studies detailed and optimized the application of PBA in the antidiabetic DDSs. However, there are several challenges such as the discrepancy between apparent pKa for application and physiological pH^{52,53} and the insufficient sensitivity to the fluctuation of blood glucose level⁵⁴ impede its further application. Therefore, a number of attempts have been deployed to form the accurate and adjustable glucose-responsive capacity to achieve controllable and sustainable drug release, providing more convenient formulations with better patient compliance.

Another case of stimuli-responsive capacity is glucose oxidase (GOx) which has been widely reported as a key component in the PEG-based DDSs. GOx is an enzyme that converts β -D-glucose and oxygen into gluconic acid and H₂O₂⁵³. The intensive oxidation of H₂O₂ can induce many reactions including the dissociation of oxidation-sensitive materials. Thus, a number of DDSs choose H₂O₂ as the initiator of carrier degradation. However, the tissue inflammation induced by H₂O₂ is a challenge of GOx-based glucose-responsive DDSs⁵⁵. In general, the complexes of PEG and stimuli-responsive ingredients, because of their sustainable and controllable drug release capacity, are gradually being developed as a promising antidiabetic DDSs.

In this review, we discussed the application of PEG and PEGylated DDSs in the antidiabetic treatments by introducing several novel delivery systems and emphasizing the combination of PEGylated antidiabetic DDSs and stimuli-responsive capacity. In order to further illustrate the extensive applications of PEG in antidiabetic DDSs, several instances are provided below with a detailed description.

2 PEGylated micelles in antidiabetic treatments

Among all kinds of micelles, the amphiphilic block copolymeric micelle draws much attention as DDSs⁵⁶. Amphiphilic block copolymeric micelles are a series of thermodynamically stable colloidal dispersions consisting of amphiphilic block copolymers, being of diverse strengths such as stabilizing drugs, targeting delivery, enhancing cellular uptake^{57,58}. Three types of amphiphilic copolymeric micelles have been applied in the designing of DDSs: micelle-drug complexes are the composites of copolymeric micelles and drugs, micellar microcontainers trap drug molecules into their internal cavities to deliver them, and polyelectrolyte complexes are formed by the electronic interaction between cargoes and carriers, such as the conjugates of cationic block copolymers and polynucleotides⁵⁹.

The amphiphilic block copolymeric micelles can be prepared by the self-assembling of the amphiphilic block copolymer chains which consist of two or more types of natural or synthetic polymers with different water affinity. The hydrophobic polymers consist of the internal side of the copolymeric chain and the hydrophilic polymers, like PEG, are placed on the other side to form external surface of micelles. In fact, PEG is considered as a popular ingredient to form amphiphilic micelles⁵⁶. This unique architecture, widely known as the core-shell structure, allow micelles to deliver drugs with poor aqueous solubility in the water phase by loading them in the hydrophobic core of micelles⁶⁰. In the PEG-contained amphiphilic block copolymeric micelles, the inner space of this spherical colloid encapsulates drugs and the outer PEG chains allow the micelle immune to unwanted results such as enzymolysis and aggregation^{61,62}.

Many sorts of chemicals are reported in the development of PEG-contained amphiphilic block

copolymeric micelles. For instance, synthetic polypeptides have been applied because they are highly biocompatible and biodegradable. Li Zhao and coworkers chose poly (L-glutamic acid) (PGA) to prepare monomethoxy PEG-*b*-poly (L-glutamic acid-*co*-N-3-L-glutamylamidophenylboronic acid) which designated as mPEG-*b*-P (GA-*co*-GPBA) micelles by modifying mPEG-*b*-PGA with 3-amino phenylboronic acid (APBA) to deliver insulin²². The whole synthetic route can be divided into two major steps (scheme 2). Firstly, the copolymers mPEG-*b*-PGA were synthesized by the ring-opening polymerization (ROP) of μ -Benzyl-L-glutamate-N-carboxyanhydride (BLG-NCA) which followed by the debenzylation. Secondly, APBA molecules were coupled with the pendent carboxyl groups of GA units to afford copolymers mPEG-*b*-P (GA-*co*-GPBA). Afterwards, insulin was loaded into the hydrophobic core of the micelle via dialysis method in deionized water.

Scheme 2. Synthetic route of copolymers prepared by Li Zhao *et al.*

The PBA groups in the polymers can interact with excessive blood glucose to form PBA-glucose complexes. This hydrophilic variation allows the previously hydrophobic polymers to solve in the water phase and the insulin loaded in advanced scatter in the local environment. Thus, these amphiphilic copolymeric micelles synthesized in the work of Li Zhao *et al.* exhibited glucose-responsive and adjustable drug release ability. As **figure 3** exhibited, When the insulin-loaded micelles were added to phosphate buffer (PB) without any glucose (0 mg/mL), insulin released very slowly: only 12.6% of the total were released within 3 h. After the concentration of glucose increased to 3.0 mg/mL, obvious release (37.7%)

was observed for the subsequent 3 h. Switching the concentration back to 0 mg/mL, insulin release was inhibited, only 7.2% amount was released in the following 3 h. Then, as the concentration return to 3.0 mg/mL again, release behavior was recovered, verified by 16.1% release of insulin within 3 h.

Figure 3. The release profile of glucose-responsive mPEG-*b*-P (GA-*co*-GPBA) micelles

In addition, no significant difference in circular dichroism (CD) spectra was observed between the released insulin and standard insulin sample, demonstrating that the preloaded insulin maintained its conformation after release. *In vitro* cytotoxicity investigation indicated the good biocompatibility of this copolymeric system.

This micelle system was prepared by Li Zhao *et al.*, all components of the micelle are biodegradable and biocompatible, allowing safely elimination after the release of insulin. Besides, except for functioning as a hydrophilic group, PEG is also able to balance the increased immunogenicity and protect micelles from proteases⁶³ in these copolymeric systems. CD spectra verified the therapeutic validity of insulin loaded inside micelles. All these features could support the promising prospect of these copolymeric micelles as antidiabetic DDS.

Although polypeptides are of many advantages, a fatal demerit of these materials is the vulnerability to proteases which may weaken the protective effect of micelles on the loaded drug. Thus, Wu Gang and coworkers developed complex poly amino acids micelles with proteases resistance²⁴. As **figure 4** showed, PEG and poly (N-isopropylacrylamide) (PNIPAM) complex were employed as the composite shell, while poly (aspartic acid-*co*-aspartic acid phenylboronic acid) designated as P(Asp-*co*-AspPBA) and poly

193 (aspartic acid-*co*-aspartic acid glucosamine-*co*-aspartic acid nitrilotriacetic acid) designated as
 194 P(Asp-*co*-AspGA-*co*-AspNTA) functioned as the composite core. Insulin was connected to the divalent zinc
 195 ions which coordinated with NTA groups located on the P(Asp-*co*-AspGA-*co*-AspNTA) copolymeric chains.
 196 The glucose sensitivity of these composite micelles was derived from the PBA/GA complexation. PNIPAM
 197 played a crucial role in the protection of micelles from proteolysis by collapsing to form a hydrophobic
 198 shield. As expected, the resistance to proteases and improved blood glucose regulation capacity was
 199 observed. Under abnormally high blood glucose level, the interaction between glucose and PBA moieties
 200 gradually leads to the swelling and disassembly of complex micelles and the release of insulin.

201
 202 **Figure 4.** Schematic of the preparation and release process of complex micelles prepared by Wu Gang *et al.*²⁴
 203

204 Rujiang Ma *et al.* devised a type of glucose-responsive complex micelle consisting of block copolymer
 205 PEG-*b*-poly (acrylic acid-*co*-acrylamidophenylboronic acid) (PEG-*b*-P(AA-*co*-APBA)) and glycopolymer
 206 poly (acrylic acid-*co*-acrylglucosamine) (P(AA-*co*-AGA))²⁵. In this complex micelle system prepared by
 207 Rujiang Ma and coworkers, PEG chains on the outer layer functioned as a hydrophilic shell against
 208 aggregation. Another ingenious strategy is the introduction of glycopolymer: the most suitable pH for
 209 glucose-responsiveness is the apparent pKa of PBA (around pH 9) which is much higher than physiological
 210 pH (around 7.4), so the glucose sensitivity is restricted under physiological condition. Due to the
 211 complexation between PBA and glycopolymer, the apparent pKa of PBA was decreased and the glucose

sensitivity was enhanced.

Except for the enzyme degradation, undesirable aggregation is another obstacle to insulin delivery and application. For example, insulin amyloid deposition has been found at the sites of frequent subcutaneous insulin injections⁶⁴. This objectionable aggregation generally means the weakened hypoglycemic activity of insulin²³ and the increase of its immunogenicity⁶⁵. Besides, these deposits also cause trouble in the production, storage and transportation of insulin⁶⁶.

In recent decades, nanocage is gradually concerned as an alternative to traditional DDSs and PEGylation is regarded as an effective method of nanocage functionalization to obtain various advanced properties⁶⁷. A PEG-phosphatidylethanolamine (PEG-PE) micelle system was developed to achieve the reversion of insulin aggregation, inspired by the GroEL-GroES chaperonin system of *Escherichia coli*²³. These diblock copolymeric micelles functioned as nanocages to concentration-dependently reverse the dithiothreitol (DTT)-induced insulin aggregation.

Insulin is a hypoglycemic protein with 51 amino acids, composed of two chains designated as A chain with 21 amino acids and B chain with 30 amino acids. These two chains are connected by two disulfide bonds between A and B chains. DTT can cut off these two disulfide bonds to afford separated unfolded peptide chains and the interaction between the hydrophobic parts of these chains finally produces the aggregations. Specifically, these nanocages were able to trap A and B chains of insulin cleaved by DTT, screening the interaction between their hydrophobic moieties which is the main factor of sedimentary formation. Besides, the separated A and B chains were able to reconnect with each other to afford native insulin with hypoglycemic activity. This process can be verified by the MALDI-TOF mass spectra and hypoglycemic effect in mice. CD spectroscopy suggested that PEG-PE micelles stabilized the secondary structure of native insulin, preventing chains from false folding.

Jun Wang and coworkers devised and prepared a type of cholic acid (CA)-PLGA-*b*-(polyethyleneimine (PEI)-PEG) micelles to load insulin on their surface through electrostatic interaction (**figure 5**)²⁶. An

attractive point of this work reported by Jun Wang *et al.* is the combination of PLGA, PEI and PEG. PLGA has been considered as an ideal material to build micro/nano structure for drug delivery^{68,69}. However, according to existing reports, the degradation of PLGA could produce an local acidic atmosphere⁷⁰ which may cause negative effects on the loading proteins and peptides but can be ameliorated by introducing PEI into the delivery system⁷¹. However, the high cytotoxicity of PEI with large molecular weight (such as 25kDa) derived from its excessive positive charge impedes its application^{72,73}. Thus, PEG was introduced into the system combining with low molecular weight PEI to ensure the safety of polymeric delivery system, and the validity of these strategies have been confirmed^{73,74}. Insulin was able to efficiently loaded on the cationic polymeric micelles via the electrostatic force between the abundant cations on PEI-PEG layer and insulin. Extended blood glucose regulation time was observed in *in vivo* investigation.

Figure 5. Preparation of the microsphere loaded with CA-PLGA-*b*-(PEI-PEG) micelles-insulin conjugates²⁶.

3 PEGylated vesicles in antidiabetic treatments

Vesicles are a series of particles sharing a similar structure which consist of a lipid bilayer membrane and an internal hollow space separated from the outside. The bilayer membrane is composed of the hydrophilic "heads" which are generally forming the surface of the membrane and hydrophobic "tails" which are buried under "heads". Biologically, vesicles including liposomes and exosomes are of great importance in the transportation, communication and other metabolic processes of various cells. The potential of vesicles as drug delivery systems has been widely reported⁷⁵⁻⁷⁷ such as paclitaxel-loaded exosomes modified by PEG and ligand treating non-small-cell lung carcinoma (NSCLC) with prolonged

circulation time⁷⁸.

Inspired by bio-generated vesicles, synthetic ones are also have been developed to deliver drugs. For instance, inspired by native vesicles, Wanyi Tai *et al.* devised a biomimetic polymersome nanovesicle system with an acid-sensitive capacity²⁸. This copolymeric vesicle employed PEG as the hydrophilic “heads” and ketal-modified polyserine (PEG-P (Ser-Ketal)) as the hydrophobic “tails” to form the bilayer membrane. Insulin, glucose oxidase (GOx) and catalase (CAT) were loaded in the hollow space of the vesicle. Drugs were well encapsulated while glucose molecules, due to their small size, were able to penetrate into the inside of the copolymer membrane. Afterwards, the interaction between glucose and GOx afforded gluconic acid and H₂O₂, leading to the local pH decrease. Meanwhile, H₂O₂ generated from the aforementioned process was converted to oxygen by CAT to avoid damaging other cellular components and the deactivation of GOx⁷⁹⁻⁸². As the result of pH decrease, the ketals located on the polyserine segments of copolymers dissociated through acidic hydrolysis, causing hydrophilic conversion (**figure 6 B**) of entire copolymers in aqueous phase (like blood). Water-soluble copolymers without ketal moieties solved in the solution and the copolymeric membrane gradually fractured. Finally, insulin loaded in advance was released (**figure 6 A**).

Figure 6. Schematic of the degradation of acid-sensitive diblock copolymer nanovesicles.

275 The PEG-contained copolymeric nanovesicles were prepared by Wanyi Tai *et al.* exhibiting the
 276 glucose-responsive capacity. A low level of insulin release was observed under 100 mg/dL glucose or
 277 glucose-free condition in PBS buffer over 12 h, compared with the rapid release under hyperglycemic
 278 condition. More importantly, with alternative conversion between normoglycemia and hyperglycemia
 279 every 2 h, insulin release exhibited a pulsatile trend correspondingly (figure 7).

280
 281 **Figure 7.** Pulsatile insulin release profile of PEG-P (Ser-Ketal) nanovesicles.
 282

283 Difference up to 3-fold in release rate was observed when the glucose concentration altered. However,
 284 this trend gradually diminished as this circulation continued. A possible reason could be the gradual
 285 dissociation of vesicles and the leakage of enzymes.

286 Except for Wanyi Tai and coworkers, the applications of vesicles in the antidiabetic DDSs are also
 287 studied by others. Anna Kim *et al.* reported a distearoylphosphoethanolamine-PEG (DSPE-PEG)-coated
 288 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) liposomes to reduce the uptake of liposome by
 289 reticuloendothelial system (RES) in parenteral administration³⁰. After coated by DSPE-PEG, the liposomes
 290 were of more uniform size with enhanced aggregation resistance, and the circulation time was also
 291 extended by 1 h.

292 In addition to individually applied, vesicles are also able to combine with other delivery systems.
 293 Rachna Rastogi *et al.* developed a poly (caprolactone)-PEG-poly (caprolactone), which designated as
 294 PCL-PEG-PCL, copolymeric vesicle system to encapsulated insulin-deoxycholate composite micelles²⁷.

295 Compared with free insulin, the encapsulation efficiency of complex micelles was enhanced by around
 296 10-50%. Burst insulin release was weakened and the efficacy time was prolonged by 2 h, but the increased
 297 hydrophobicity of the delivery system exerted a negative influence on its pharmacological effects which
 298 emphasize the critical role of equilibrium between hydrophilicity and lipophilicity.

299 Another case is microneedles-vesicles composite delivery system. Microneedles (MNs) have been
 300 introduced to antidiabetic DDSs to achieve painless transdermal administration which is able to promote
 301 patient compliance due to their unique properties⁵³. MNs (**figure 8**) have been extensively explored for the
 302 transdermal administration of various substances such as small molecule drugs⁸³, proteins⁸⁴ and particles⁸⁵,
 303 and diverse type of MNs including hollow, solid, coated, dissolving and hydrogel forming⁴⁹ are also
 304 developed by various materials. The application of MNs in antidiabetic DDSs have been systematically
 305 reported^{48,49}.

306
 307 **Figure 8.** Images of different shapes of MNs (A-I)⁴⁸ and different type of MNs including solid MNs (J), hollow MNs (K),

dissolving MNs (L), degradable MNs (M), and bioresponsive MNs (N)⁸⁶.

The painless and efficient transdermal delivery capacity of MNs is derived from their unique architecture. As **figure 9** displayed, stratum corneum (SC) with a thickness of 10–15 μm is considered as the main obstacle for transdermal administration. According to reports, only sufficiently lipophilic substances with molecular weight lower than 500 Da⁸⁷, which is too small for most of the vesicles, could diffuse into SC. As the result, common transdermal administration is restricted for vesicles. Fortunately, nerves are located a few hundred microns below SC⁸⁸. Thus, the painless administration can be achieved through bypassing the SC without or slightly touching nerves, inducing little or no pain. Besides, compared with conventional transdermal formulations which are highly restricted by the diffusion limit of SC, MNs are able to efficiently deliver the diver types of drugs without SC impedance. The introduction of MNs allow the vesicles which are too large to penetrate SC by self-diffuse to cross this screen with high efficiency, and glucose-responsive vesicles endow formulations with sustainable and controllable release, achieving optimal dosage distribution. The MNs-vesicles complex delivery systems integrate both the efficient transdermal administration and glucose-responsive capacity.

Figure 9. The transdermal administration of vesicles performed by microneedles array.

Xiuli Hu *et al.* integrated self-assembling amphiphilic block copolymeric vesicles which were composed of PEG, polyserine and phenylboronic ester (PBE) with microneedles array to form a MNs/vesicles complex delivery system to achieve sustainable and controllable release¹⁸. Cross-linked hyaluronic acid (HA) was adopted to form the microneedle structure. **Figure 10 A** shows the architecture of mPEG-*b*-P (Ser-PBE)

330 vesicles-loaded MNs array. **Figure 10 B** exhibits that excessive blood glucose concentration causes the
 331 disassociation of vesicles and the consequent insulin release. **Figure 10 C** displays that the origin of H_2O_2
 332 which was directly responsible for the dissociation of vesicles is the interaction between GOx encapsulated
 333 in the vesicles and the glucose penetrating into the inside of vesicles.

334
 335 **Figure 10. A** exhibits the architecture of MNs loaded with mPEG-b-P(Ser-PBE) vesicles; **B** displays the glucose-induced
 336 insulin release; **C** is the degradation reaction of copolymeric vesicles.

337
 338 In the presence of H_2O_2 , copolymers lost their PBE groups and transformed to hydrophilic molecules,
 339 being able to solve in the aqueous phase. Consequently, gradual degradation of vesicles led to the release
 340 of preloaded insulin. Xiuli Hu *et al.* adopted the strategy mentioned above to endow the vesicles with
 341 glucose-responsive function: GOx was introduced to catalyze the conversion from glucose to gluconic acid

and afford H_2O_2 which is responsible for the disassembly of vesicles. These vesicles were encapsulated into microneedles formed by cross-linked HA, since HA is highly biocompatible with appropriate stiffness to penetrate skin. Once the plasma glucose level was abnormally high, surplus glucose penetrated the HA membrane into the inside of vesicles, reacting with GOx to yield H_2O_2 , leading to the dissociation of vesicles and the release of insulin loaded in advance. The *in vivo* influence was carefully evaluated: the biocompatibility of this formulation was acceptable, along with the negligible hypoglycemic risk. Rapid glucose-responsive insulin release was observed under hyperglycemia and once reaching normoglycemia, the release rate was restrained. On the one hand, the glucose-sensitive drug release capacity of this MNs loaded with mPEG-b-P(Ser-PBE) vesicles reduce the risk of undesirable side effects such as hypoglycemia and potential damage induced by H_2O_2 to cells; on the other hand, this MNs allows the optimized dosage distribution for drug release, significantly prolonged blood glucose regulation time and administration interval.

In another case of the composite MNs delivery system reported by Jicheng Yu and co-workers²⁹, a type of MNs matrix containing hypoxia and H_2O_2 dual-sensitive vesicles was developed based on a similar strategy. The loaded copolymeric vesicles, designated as PEG-P (Ser-S-NI) vesicles, were composed of PEG and polyserine modified by 2-nitroimidazole through thioether bridge. The H_2O_2 and hypoxia-responsive capacity derived from the thioether and 2-nitroimidazole respectively. The thioether was transformed to sulfone after reacting with H_2O_2 , this oxidation leading to the hydrophilic conversion of polymer^{89,90}. Simultaneously, 2-nitroimidazole converted to hydrophilic 2-aminoimidazole under hypoxia condition which was mediated by the transformation from glucose to gluconic acid^{91,92}. In this composite system, the hypoxia-responsive 2-nitroimidazole parts enhance the glucose sensitivity of delivery systems, and the H_2O_2 -responsive thioether parts consume excessive H_2O_2 generated by GOx, avoiding negative effects including inflammation.

4 PEGylated nanoparticles (NPs) in antidiabetic treatments

The benefits of PEGylation to NPs have been systematically summarized⁹³ and verified by many studies^{20,31-34,36,38,39,94-96}. Basically, PEG as ingredients could resolve the instability of insulin in the harsh formulation conditions, while poly (D, L-lactide-co-glycolide acid) (PLGA) is a type of polymer that has already been successfully applied in biomacromolecule delivery⁶⁹. Yusuf Haggag and coworkers employed double emulsion technique to prepare a series of NPs consisting of poly (D, L-lactic-co-glycolic acid) (PLAG)-PEG diblock polymers to optimize the entrapment efficiency of insulin³¹. According to the experimental results, part of PLGA-PEG polymers via homogenized insulin-loading method optimized their entrapment efficiency and release kinetics of insulin. The *in vivo* studies revealed the aggregation resistance, improved stability and the maximum retention of hypoglycemic bioactivity of insulin during the whole release process. Moreover, the PLGA-PEG diblock copolymeric NP system devised by Yusuf Haggag *et al.* exhibited a marked insulin sustainable release manner.

A similar PLGA-PEG NPs system was designed by Sunandini Chopra and coworkers³⁴. The difference was that they added zinc ions to insulin to form the insulin-Zn hexamers via the chelation first, then co-assembled with PLGA-PEG under a carefully adjusted pH nanoprecipitation condition to form NPs. Finally, after a PBS washing process, the insulin-Zn PLGA-PEG NPs were afforded (**figure 11**). NPs prepared via this complexation between zinc ion and insulin exhibit significant improvement (about 10-fold) in insulin loading capacity.

Figure 11. Schematic of the preparation of insulin-Zn complex and the NPs developed by Sunandini Chopra and

In the work of Shelesh JAIN and Swarnlata SARAF, PEG significantly extended the efficacy time of repaglinide loaded by PLGA-based NPs from 1 day to 1 week with equivalent therapeutic effect³⁹. Two types of NPs designated as RPGNP1 and RPGNP2 were prepared in this work, based on PLGA and mPEG-PLGA copolymer respectively. The loading capacity of pure PLGA NPs was 58.7 ± 1.3 and the mPEG-PLGA was less than the former, being 45.8 ± 1.2 . *In vitro* release experiments indicated that both of these two formulations experienced an initial burst release and a following sustained release process. However, different trends were observed in the *in vivo* investigations. The blood glucose level of diabetic rats treated by PLGA NPs decreased within the first 24 h and began to climb afterward, while the hypoglycemic effect of mPEG-PLGA NPs maintained over 7 d (**figure 12**). A possible reason could be the different affinity to liver macrophages: RPGNP2 were hardly identified by liver macrophages due to their PEG structure and able to retain for a relatively long time, while RPGNP1 could be rapidly identified and neutralized by liver macrophages without the PEG sheltering effect.

Figure 12. Blood glucose level of different *in vivo* experimental groups in the work of Shelesh JAIN and Swarnlata SARAF.

Yanan Shi *et al.* prepared a different type of PLGA-PEG NPs, with Fc modified for the oral delivery of

404 exenatide³³. Exenatide is a GLP-1 analogue with 39 amino acids. GLP-1 is a versatile peptide generated by
405 the proglucagon gene, mainly produced by the intestinal L-cells⁹⁷. GLP-1 have been widely concerned as
406 incretin hormones to treat diabetes^{98,99}. However, a fatal demerit of natural GLP-1 is extremely short
407 lifespan. Due to the high affinity with plasma dipeptidyl peptidase 4 (DPP-4), GLP-1 can be neutralized
408 within 2 min⁹⁷. By contrast, the half-life of exenatide is 2.4 h¹⁰⁰. The Fc-targeted NPs could bind to Fc
409 receptor which is expressed on the epithelial cells in the small intestine that could help the absorption of
410 NPs. The *in vitro* and *in vivo* studies verified the better cell uptake and hypoglycemia maintaining
411 performance. Their group also developed low molecular weight protamine (LMWP)-contained PEG-PLGA
412 NPs for the oral delivery of Zn-exenatide complexes³⁸. In this delivery system, the LMWP could increase
413 the penetrability of the whole delivery system which was confirmed by the cellular uptake experiment
414 compared with the pure copolymeric delivery system, the bioavailability also exhibited great improvement.

415 Similar to the strategy of Jun Wang *et al.*, using the electrostatic interaction to connect drugs and
416 carriers, Fei Tong prepared PEG-*b*-(PELG₅₀-*g*-PLL₃) polymeric NPs to carry exenatide via electrostatic force
417 between the negative exenatide molecules and positive polymers under pH 7.4 (**figure 13 A**)³⁷. As Fei Tong
418 reported, the loading efficiency of these PEG-*b*-(PELG₅₀-*g*-PLL₃) NPs on exenatide was 12.11%. The
419 cumulative release profile indicated that the release of exenatide displayed a very stable and sustainable
420 manor (**figure 13 B**), and the observation of blood glucose level revealed a significantly prolonged
421 hypoglycemic activity (**figure 13 C**). Besides, alleviated diabetic nephropathy was also observed in this
422 study.

Figure 13. A: formation of exenatide-loaded PEG-b-(PELG₅₀-g-PLL₃) NPs; **B:** cumulative release profile of NPs; **C:** blood glucose concentration of groups treated differently³⁷.

In addition to delivery GLP-1 analogues, according to Tianqi Nie *et al.* reported, plasmids DNA encoding GLP-1 were also able to be delivered by NPs³⁶. DNA formulations are of various advantages but the rapid degradation of pure DNA and the poor ability to cross the mucus layer in the gastrointestinal tract are still the main challenges in their applications^{36,101}. PEI has already been reported widely as an efficient transfection compounds¹⁰²⁻¹⁰⁴. As **figure 14** showed, in the work of Tianqi Nie *et al.*, plasmid DNA encoding GLP-1 was complexed with linear PEI to form NPs. Afterwards, DPPC and 1,2-dimyristoyl-*rac*-glycero-3-mPEG-2000 (DMG-PEG) were adopted to coating NPs, forming linear PEI/plasmid DNA NPs with a hydrophilic and electrostatically neutral shell which could benefit the penetration process of mucus layer since its highly hydrophilic with abundant cationic charges via an exquisite method named as flash nanocomplexation (FNC).

Figure 14. Preparation of linear PEI/plasmid DNA NPs coated by DPPC/DMP-PEG via FNC technology and the expected penetration process through the gastrointestinal tract³⁶.

In vitro investigations indicated the obviously reduced cytotoxicity induced by the DPPC/DMG-PEG shell and the high transfection efficiency in A549 and HeLa cell lines. *In vivo* experiments pointed out the high efficiency of transfection in the lung and liver, while the good biocompatibility was verified by ameliorated liver damage observed in the toxicity evaluation. Besides, stable expression of GLP-1 resulted in sufficient blood glucose regulation capacity, confirming the potential of the FNC-prepared linear PEI/plasmid DNA NPs coated by DPPC/DMP-PEG.

In order to further improve the physiochemical properties to promote the insulin delivery capacity of PEGylated NPs, pharmaceutical spray drying was adopted in the preparation of NPs (**figure 15**). Various benefits to drug encapsulation of this formulation technology have been reported^{105,106}.

Figure 15. SEM images of several NPs produced by spray drying collected by Cordin Arpagaus *et al.*¹⁰⁶

Spray freeze drying (SFD) is deriving from the general spray drying have been applied to prepare NPs as insulin carriers¹⁰⁷. In this technology, the notable advantage is it can maximum retain the insulin's bioactivity due to the drying process under low temperature.

Fei Yu *et al.* took the advantage of SFD to form a type of hydroxypropyl methylcellulose phthalate-coated hard gelatin capsules (HP55) loaded with mono-dispersed microparticles containing insulin-loaded PLGA-lipid-PEG nanoparticles (designated as micro-particles@INS-PLGA-lipid-PEG NPs) for oral administration of insulin (**figure 16**), exhibiting excellent entrapment efficiency (92.3%), much more cellular uptake efficiency than the naked insulin and prolonged decreasing blood glucose level in diabetic mice with oral administration³⁵. This kind of NPs combine the advantages of both polymeric NPs and liposomes¹⁰⁸. Three different functional domains constitute the NPs: a hydrophobic PLGA core as the insulin carrier, an amphiphilic middle layer composed of soybean phosphatidylcholine (SPC) promotes the delivery efficiency and a PEG shell provides physiological stability. Gradient insulin release and elimination were observed after oral administration of the prepared LPNs compared with the rapid release rate induced by subcutaneous injection.

Sampath Malathi and coworkers prepared a series of D- α -tocopherol PEG 1000 succinate (TPGS)-emulsified PEG-capped PLGA NPs (ISTPPLG NPs) for insulin delivery via oral administration³². The rat trials suggested that the ISTPPLG NPs could successfully decrease the serum glucose level and last for 24 h. Notably, the ISTPPLG NPs showed a regenerative effect of the liver, kidneys and pancreas on diabetic rats compared to normal control rats.

5 PEGylated hydrogels in antidiabetic treatments

Hydrogel is a type of water-swollen networks mainly consisting of polymer¹⁰⁹, and PEG is a widely used

ingredient for hydrogels which have been extensively studied to achieve controllable and sustainable antidiabetic drug delivery. Plenty of studies report the DDSs based on hydrogels^{41-46,110-115}. Basically, a wide range of substrates can be loaded in the PEG-based hydrogel systems due to their unique structural characters: the highly customizable block length of PEG and other components of hydrogel allow the adjustment of equilibrium between hydrophobicity and hydrophilicity, enabling the universality of different molecules¹¹⁶. Another advantage of copolymeric hydrogels is the diverse stimuli-responsive capacity. Thermosensitive, pH-responsive hydrogels and many other species have been developed and applied in DDSs¹¹⁷. Besides, varying the ratio of different components and combining two or more distinct copolymers also could improve loading capacity. Some examples of diabetes treatment are listed below.

Thermosensitive hydrogels are the most investigated stimuli-sensitive species¹¹⁸, already been applied in the delivery of biomacromolecules¹¹⁹. Phase diagrams reveal the conversion between liquid and solid (figure 16). The lower critical solution temperature (LCST) is the lowest temperature that the polymer remains soluble in aqueous solvent which is injectable. Once beyond the LCST, polymer will transfer to solid gel state to form local drug storage.

Figure 16. Phase diagrams mark the lower critical solution temperature (LCST) and the upper critical solution temperature (UCST) as the temperature barriers between monophasic and biphasic mixture¹¹⁷.

Up to date, thermosensitive hydrogels have already been adopted to deliver antidiabetic drugs. Yipei Chen *et al.* described a series of injectable thermosensitive hydrogels to achieve sustained release of liraglutide (lira)⁴¹. The hydrogels were composed by poly (ϵ -caprolactone-*co*-glycolic acid)-PEG-poly

(ϵ -caprolactone-*co*-glycolic acid) (PCGA-PEG-PCGA), obtained via typical ROP, being of similar molecular weights while the ratio of ϵ -caprolactone-*co*-glycolide was various. As reported, these biocompatible copolymers were able to convert to gel from aqueous solution as the ambient temperature increased, which means that copolymers loaded lira were injectable under room temperature, once these thermosensitive materials enter the body, they could form stable hydrogels *in situ* to build drug storages and release pre-encapsulated lira continuously. This copolymer hydrogel formulation fulfills the demand of both sustain drug delivery and painless administration. Meanwhile, pancreatic function benefits were observed, indicating the considerable clinical value of these thermosensitive hydrogels.

The loaded drug, lira, is a palmitoyl-acylated derivative of GLP-1. As **figure 17** exhibited, the replacement of lysine with arginine at position 34 and the linkage of a 16-carbon fatty acid at position 26¹²⁰ impede the degradation induced by DPP-4¹²¹, extending the half-life of lira (11-13 h) compared with the unmodified GLP-1 (no more than 2 min)¹²². Besides, various pharmacological activities including the normalization of serum glucose level, the regulation of cardiovascular situation¹²³ and the promotion of β -cell proliferation¹²⁴ have been reported.

Figure 17. Structure of liraglutide¹²⁵.

A PLGA-PEG-PLGA triblock copolymeric thermosensitive hydrogel was reported⁴² as the carrier of another versatile GLP-1 receptor agonists lixisenatide (lix) ¹²⁶⁻¹²⁸ since the electronic interaction between lixi and PLGA-PEG-PLGA benefit the stability of lixi. Except for PLGA-PEG-PLGA, PCGA-PEG-PCGA copolymers and the mixture of these two copolymeric systems were also investigated. According to the literature, blending hydrogels are of more stable degradation performance *in vivo* than PLGA-PEG-PLGA or PCGA-PEG-PCGA hydrogel alone. Most of all, as the pharmacokinetic study of mixture suggesting,

remarkable pharmaceutical improvements were observed including prolonged half-life time and enlarged AUC (table 2).

Table 2. Pharmacokinetic investigation unfolded the enhancement of hydrogel formulation⁴².

sample	C _{max} ^a (ng/mL)	^b T _{max} (h)	^c t _{1/2z} (h)	AUC _(0–last) (h ng/mL) ^d	MRT ^e
free Lixi	106.4	1.0	2.2	378.9	2.8
Lixi/Gel	24.5	0.5	30.3	2891.6	94.6

a: maximum plasma concentration; b: time required to reach the maximum plasma concentration; c: plasma half elimination time; d: area under the curve; e: mean retention time.

Divya Sharma and Jagdish Singh prepared a PLGA-PEG-PLGA copolymeric hydrogel system to load chitosan-zinc-insulin complexes⁴⁰. The complex of insulin and zinc and the application of oleic-modified chitosan polymer significantly stabilized insulin and its distribution process among this thermosensitive injectable hydrogel. *In vivo* investigation indicated the more stable blood concentration of insulin and the prolonged blood glucose regulation time compared with free insulin.

Mei Zhang and coworkers⁴⁴ reported an oxidation-responsive hydrogel polymerized by 4-arm-PEG20k-SH and H₂O₂-breakable diacrylate (figure 18). Fluorescein isothiocyanate (FITC) insulin and GOx were loaded into the hydrogel network.

natural polysaccharide composed of a series of linear copolymers of D-glucosamine and N-acetyl-D-glucosamine¹³⁰. Due to properties such as good biocompatibility and encapsulation capacity of negatively charged proteins and peptides, CS has captured much attention in DDSs^{131,132}. However, CS requires further structural modifications to improve its loading capacity before its application¹³³⁻¹³⁵. PEGylation could be considered as an acceptable method to extend blood half-life time¹³⁶ and further enhance the biocompatibility of CS¹³⁷. Bahman Vasheghani Farahani and coworkers fabricated a glucose-responsive semi IPN hydrogel by free radical cross-linking polymerization of CS, acrylamide (AAM) and PEG, using hydrogen peroxide as the initiator and N, N'-methylenebisacrylamide (MBA) as the crosslinker⁴⁵. **Figure 19** displays its exact structure.

Figure 19. SEM image of chitosan semi-IPN hydrogel (A) and insulin loaded chitosan semi-IPN hydrogel (B)⁴⁵.

The glucose-responsive property was generated mainly by GOx while CAT also contributed. Insulin was loaded inside the hydrogel by the swelling-diffusion technique. Interestingly, increased PEG ratio led to the rise of swelling ratio, drug loading capacities and entrapment efficiency. *In vitro* investigation showed that per 0.1 g of hydrogel released 150 units of insulin under 500 mg/dL of glucose concentration, and the insulin release rate can be flexibly adjusted by altering the ratio of PEG (**figure 20**).

Figure 20. *In vitro* insulin release profiles of semi IPN hydrogels with different PEG ratio prepared by Bahman Vasheghani Farahani *et al.*⁴⁵

569 **6 Conclusion**

570 Diabetes mellitus is a severe chronic metabolic disorder that causes huge economic losses and physical
571 pain of patients. Numerous DDSs for antidiabetic drugs, including micelles, vesicles, nanoparticles,
572 microneedles and hydrogels, have been developed to achieve efficient and convenient administration. PEG
573 is a series of amphiphilic polymers which have been studied elaborately in DDSs. The PEG modified DDSs
574 allow multiple physiochemical, pharmacokinetic or pharmacodynamic promotions of antidiabetic drugs
575 such as insulin, GLP-1 analogues and others.

576 The large number of combinations between PEG and other natural or synthetic molecules such as
577 chitosan and PLGA provide abundant types of carriers with diverse characters to fulfill complex demands
578 of drugs. Generally, in the micelle systems, PEG functions as the hydrophilic tails to accelerate the
579 self-assembly of amphiphilic copolymers to afford micelles. Besides, the hydrophilic shell formed by PEG is
580 able to shelter micelles and loaded molecules from undesirable enzymolysis. In the meantime, the
581 purposive modified hydrophobic heads of copolymers could endow micelles with stimuli-responsive
582 capacity, such as the phenylboronic acidified hydrophobic heads could perceive the slight fluctuation of
583 blood glucose level, to achieve controllable and sustainable drug release. Basically, due to the
584 sophisticated structures, several ingredients could be loaded inside the PEGylated vesicles simultaneously.
585 Therefore, vesicles could respond to multiple physiological stimuli to perform a promoted release profile.
586 The highly improved drug delivery efficiency of PEGylated NPs also has been proven such as extended *in*
587 *vivo* half-life time. In the designing and preparation of hydrogels, PEG is widely adopted as an ideal
588 component to build these porous networks. The various combinations between PEG and other natural or
589 artificial materials provide plenty of strategies to develop DDSs. For instance, the thermosensitive
590 hydrogels obtained via integrating thermosensitive materials and PEG exhibit significantly extended
591 internal lifespan.

592 This review highlights the advantages and the versatility of PEG in the designing and preparation of
593 antidiabetic DDS. Benefits like extended plasma half-life, reduced aggregation, enhanced delivery
594 efficiency, improved biocompatibility and stimuli-responsive capacity have been summarized. Predictably,
595 PEG will be continuously studied as an important chemical to develop DDS in the treatment of diabetes
596 mellitus.

597

Acknowledgement

This work was supported by National Natural Science Foundation of China (81673296) and National Key R&D Program of China (2018YFA0901701).

- 1 Sinclair, A., Saeedi, P., Kaundal, A., Karuranga, S., Malanda, B. & Williams, R. Diabetes and global ageing among 65–99-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, 9(th) edition, *Diabetes Res Clin Pract*, 162 (2020) 108078, doi:10.1016/j.diabres.2020.108078.
- 2 Saeedi, P., Salpea, P., Karuranga, S., Petersohn, I., Malanda, B., Gregg, E. W., Unwin, N., Wild, S. H. & Williams, R. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition, *Diabetes Res Clin Pract*, 162 (2020) 108086, doi:10.1016/j.diabres.2020.108086.
- 3 L Castano, a. & Eisenbarth, G. S. Type-I Diabetes: A Chronic Autoimmune Disease of Human, Mouse, and Rat, 8 (1990) 647–679, doi:10.1146/annurev.iy.08.040190.003243.
- 4 Simos, Y. V., Spyrou, K., Patila, M., Karouta, N., Stamatis, H., Gournis, D., Dounousi, E. & Peschos, D. Trends of nanotechnology in type 2 diabetes mellitus treatment, *Asian Journal of Pharmaceutical Sciences* (2020), doi:10.1016/j.ajps.2020.05.001.
- 5 Chatzakis, C., Goulis, D. G., Mareti, E., Eleftheriades, M., Zavlanos, A., Dinas, K. & Sotiriadis, A. Prevention of gestational diabetes mellitus in overweight or obese pregnant women: A network meta-analysis, *Diabetes Res Clin Pract*, 158 (2019) 107924, doi:10.1016/j.diabres.2019.107924.
- 6 Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., Shaw, J. E., Bright, D., Williams, R. & Committee, I. D. F. D. A. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition, *Diabetes Res Clin Pract*, 157 (2019) 107843, doi:10.1016/j.diabres.2019.107843.
- 7 Zuo, X., Dong, Z., Zhang, P., Zhang, P., Chang, G., Xiang, Q., Zhu, X., Zhou, J., Qiao, C., Yang, Y., Qin, Y. & Lou, P. Effect of cognitive behavioral therapy on sleep disturbances and quality of life among adults with type 2 diabetes mellitus: A randomized controlled trial, *Nutrition, Metabolism and Cardiovascular Diseases* (2020), doi:10.1016/j.numecd.2020.06.024.
- 8 Razaz, J. M., Rahmani, J., Varkaneh, H. K., Thompson, J., Clark, C. & Abdulazeem, H. M. The health effects of medical nutrition therapy by dietitians in patients with diabetes: A systematic review and meta-analysis: Nutrition therapy and diabetes, *Prim Care Diabetes*, 13 (2019) 399–408, doi:10.1016/j.pcd.2019.05.001.
- 9 Reyes-García, R., Moreno-Pérez, Ó., Tejera-Pérez, C., Fernández-García, D., Bellido-Castañeda, V., López de la Torre Casares, M., Rozas-Moreno, P., Fernández-García, J. C., Marco Martínez, A., Escalada-San Martín, J., Gargallo-Fernández, M., Botana-López, M., López-Fernández, J., González-Clemente, J. M., Jódar-Gimeno, E. & Mezquita-Raya, P. A comprehensive approach to type 2 diabetes mellitus - A recommendation document, *Endocrinología, Diabetes y Nutrición* (English ed.), 66 (2019) 443–458, doi:10.1016/j.endien.2018.10.013.
- 10 Harris, J. M., Martin, N. E. & Modi, M. Pegylation: a novel process for modifying pharmacokinetics, *Clin Pharmacokinet*, 40 (2001) 539–551, doi:10.2165/00003088-200140070-00005.
- 11 D’Souza A, A. & Shegokar, R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications, *Expert Opin Drug Deliv*, 13 (2016) 1257–1275, doi:10.1080/17425247.2016.1182485.
- 12 Li, W., Zhan, P., De Clercq, E., Lou, H. & Liu, X. Current drug research on PEGylation with small molecular agents, *Progress in Polymer Science*, 38 (2013) 421–444, doi:10.1016/j.progpolymsci.2012.07.006.
- 13 Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G. & Misra, A. PEG - a versatile conjugating ligand for drugs and drug delivery systems, *J Control Release*, 192 (2014) 67–81, doi:10.1016/j.jconrel.2014.06.046.
- 14 Wang, J. Z., You, M. L., Ding, Z. Q. & Ye, W. B. A review of emerging bone tissue engineering via PEG

648 conjugated biodegradable amphiphilic copolymers, *Mater Sci Eng C Mater Biol Appl*, 97 (2019) 1021–1035,
649 doi:10.1016/j.msec.2019.01.057.

650 15 Mishra, P., Nayak, B. & Dey, R. K. PEGylation in anti-cancer therapy: An overview, *Asian Journal of*
651 *Pharmaceutical Sciences*, 11 (2016) 337–348, doi:10.1016/j.ajps.2015.08.011.

652 16 Jacob, J., Haponiuk, J. T., Thomas, S. & Gopi, S. Biopolymer based nanomaterials in drug delivery systems:
653 A review, *Materials Today Chemistry*, 9 (2018) 43–55, doi:10.1016/j.mtchem.2018.05.002.

654 17 Fuks, G., Mayap Talom, R. & Gauffre, F. Biohybrid block copolymers: towards functional micelles and
655 vesicles, *Chem Soc Rev*, 40 (2011) 2475–2493, doi:10.1039/c0cs00085j.

656 18 Hu, X., Yu, J., Qian, C., Lu, Y., Kahkoska, A. R., Xie, Z., Jing, X., Buse, J. B. & Gu, Z. H2O2-Responsive
657 Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery, *ACS Nano*, 11
658 (2017) 613–620, doi:10.1021/acsnano.6b06892.

659 19 Morcol, T., Nagappan, P., Nerenbaum, L., Mitchell, A. & Bell, S. J. Calcium
660 phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin, *Int J Pharm*, 277
661 (2004) 91–97, doi:10.1016/j.ijpharm.2003.07.015.

662 20 Wang, W., Liao, L., Zhang, X., Lei, F., Zhang, Y., Liu, G. & Xie, W. An Intelligent Nanoscale Insulin
663 Delivery System, *Molecules (Basel, Switzerland)*, 23 (2018), doi:10.3390/molecules23112945.

664 21 Yu, J., Zhang, Y., Yan, J., Kahkoska, A. R. & Gu, Z. Advances in bioresponsive closed-loop drug delivery
665 systems, *Int J Pharm*, 544 (2018) 350–357, doi:10.1016/j.ijpharm.2017.11.064.

666 22 Zhao, L., Ding, J., Xiao, C., He, P., Tang, Z., Pang, X., Zhuang, X. & Chen, X. Glucose-sensitive
667 polypeptide micelles for self-regulated insulin release at physiological pH, *Journal of Materials*
668 *Chemistry*, 22 (2012), doi:10.1039/c2jm31040f.

669 23 Fang, X., Yang, T., Wang, L., Yu, J., Wei, X., Zhou, Y., Wang, C. & Liang, W. Nano-cage-mediated refolding
670 of insulin by PEG-PE micelle, *Biomaterials*, 77 (2016) 139–148,
671 doi:10.1016/j.biomaterials.2015.11.007.

672 24 Wu, G., Li, C., Liu, X., Lv, J., Ding, Y., Liu, Y., Liu, Y., Huang, F., Shi, L., An, Y. & Ma, R.
673 Glucose-responsive complex micelles for self-regulated delivery of insulin with effective protection
674 of insulin and enhanced hypoglycemic activity in vivo, *Colloids Surf B Biointerfaces*, 180 (2019) 376–383,
675 doi:10.1016/j.colsurfb.2019.05.003.

676 25 Ma, R., Yang, H., Li, Z., Liu, G., Sun, X., Liu, X., An, Y. & Shi, L. Phenylboronic acid-based complex
677 micelles with enhanced glucose-responsiveness at physiological pH by complexation with glycopolymer,
678 *Biomacromolecules*, 13 (2012) 3409–3417, doi:10.1021/bm3012715.

679 26 Wang, J., Li, S., Chen, T., Xian, W., Zhang, H., Wu, L., Zhu, W. & Zeng, Q. Nanoscale cationic micelles
680 of amphiphilic copolymers based on star-shaped PLGA and PEI cross-linked PEG for protein delivery
681 application, *J Mater Sci Mater Med*, 30 (2019) 93, doi:10.1007/s10856-019-6294-y.

682 27 Rastogi, R., Anand, S. & Koul, V. Evaluation of pharmacological efficacy of 'insulin-surfoplex'
683 encapsulated polymer vesicles, *Int J Pharm*, 373 (2009) 107–115, doi:10.1016/j.ijpharm.2009.01.022.

684 28 Tai, W., Mo, R., Di, J., Subramanian, V., Gu, X., Buse, J. B. & Gu, Z. Bio-inspired synthetic nanovesicles
685 for glucose-responsive release of insulin, *Biomacromolecules*, 15 (2014) 3495–3502,
686 doi:10.1021/bm500364a.

687 29 Yu, J., Qian, C., Zhang, Y., Cui, Z., Zhu, Y., Shen, Q., Ligler, F. S., Buse, J. B. & Gu, Z. Hypoxia
688 and H2O2 Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery, *Nano Lett*, 17 (2017)
689 733–739, doi:10.1021/acs.nanolett.6b03848.

690 30 Kim, A., Yun, M. O., Oh, Y. K., Ahn, W. S. & Kim, C. K. Pharmacodynamics of insulin in polyethylene
691 glycol-coated liposomes, *Int J Pharm*, 180 (1999) 75–81, doi:10.1016/s0378-5173(98)00408-6.

692 31 Haggag, Y., Abdel-Wahab, Y., Ojo, O., Osman, M., El-Gizawy, S., El-Tanani, M., Faheem, A. & McCarron,
693 P. Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from
694 diblock copolymers of PLGA and PEG, *Int J Pharm*, 499 (2016) 236–246, doi:10.1016/j.ijpharm.2015.12.063.

695 32 Malathi, S., Nandhakumar, P., Pandiyan, V., Webster, T. J. & Balasubramanian, S. Novel PLGA-based
696 nanoparticles for the oral delivery of insulin, *Int J Nanomedicine*, 10 (2015) 2207–2218,

doi:10.2147/IJN.S67947.

33 Shi, Y., Sun, X., Zhang, L., Sun, K., Li, K., Li, Y. & Zhang, Q. Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice, *Sci Rep*, 8 (2018) 726, doi:10.1038/s41598-018-19170-y.

34 Chopra, S., Bertrand, N., Lim, J. M., Wang, A., Farokhzad, O. C. & Karnik, R. Design of Insulin-Loaded Nanoparticles Enabled by Multistep Control of Nanoprecipitation and Zinc Chelation, *ACS Appl Mater Interfaces*, 9 (2017) 11440-11450, doi:10.1021/acsami.6b16854.

35 Yu, F., Li, Y., Liu, C. S., Chen, Q., Wang, G. H., Guo, W., Wu, X. E., Li, D. H., Wu, W. D. & Chen, X. D. Enteric-coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG nanoparticles for oral delivery of insulin, *Int J Pharm*, 484 (2015) 181-191, doi:10.1016/j.ijpharm.2015.02.055.

36 Nie, T., He, Z., Zhou, Y., Zhu, J., Chen, K., Liu, L., Leong, K. W., Mao, H. Q. & Chen, Y. Surface Coating Approach to Overcome Mucosal Entrapment of DNA Nanoparticles for Oral Gene Delivery of Glucagon-like Peptide 1, *ACS Appl Mater Interfaces*, 11 (2019) 29593-29603, doi:10.1021/acsami.9b10294.

37 Tong, F. Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block copolymer: potential implications on diabetic nephropathy, *Int J Nanomedicine*, 12 (2017) 4663-4678, doi:10.2147/IJN.S136646.

38 Zhang, L., Shi, Y., Song, Y., Sun, X., Zhang, X., Sun, K. & Li, Y. The use of low molecular weight protamine to enhance oral absorption of exenatide, *Int J Pharm*, 547 (2018) 265-273, doi:10.1016/j.ijpharm.2018.05.055.

39 Jain, S. & Saraf, S. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus, *J Diabetes*, 1 (2009) 29-35, doi:10.1111/j.1753-0407.2008.00001.x.

40 Sharma, D. & Singh, J. Long-term glycemic control and prevention of diabetes complications in vivo using oleic acid-grafted-chitosanzinc-insulin complexes incorporated in thermosensitive copolymer, *J Control Release*, 323 (2020) 161-178, doi:10.1016/j.jconrel.2020.04.012.

41 Chen, Y., Luan, J., Shen, W., Lei, K., Yu, L. & Ding, J. Injectable and Thermosensitive Hydrogel Containing Liraglutide as a Long-Acting Antidiabetic System, *ACS Appl Mater Interfaces*, 8 (2016) 30703-30713, doi:10.1021/acsami.6b09415.

42 Zhuang, Y., Yang, X., Li, Y., Chen, Y., Peng, X., Yu, L. & Ding, J. Sustained Release Strategy Designed for Lixisenatide Delivery to Synchronously Treat Diabetes and Associated Complications, *ACS Appl Mater Interfaces*, 11 (2019) 29604-29618, doi:10.1021/acsami.9b10346.

43 Wang, P., Zhuo, X., Chu, W. & Tang, X. Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity, *Int J Pharm*, 528 (2017) 62-75, doi:10.1016/j.ijpharm.2017.05.069.

44 Zhang, M., Song, C. C., Du, F. S. & Li, Z. C. Supersensitive Oxidation-Responsive Biodegradable PEG Hydrogels for Glucose-Triggered Insulin Delivery, *ACS Appl Mater Interfaces*, 9 (2017) 25905-25914, doi:10.1021/acsami.7b08372.

45 Farahani, B. V., Ghasemzaheh, H. & Afraz, S. Intelligent semi-IPN chitosan - PEG - PAAm hydrogel for closed-loop insulin delivery and kinetic modeling, *RSC Advances*, 6 (2016) 26590-26598, doi:10.1039/c5ra28188a.

46 Zhang, S., Xin, P., Ou, Q., Hollett, G., Gu, Z. & Wu, J. Poly(ester amide)-based hybrid hydrogels for efficient transdermal insulin delivery, *J Mater Chem B*, 6 (2018) 6723-6730, doi:10.1039/c8tb01466c.

47 Tanner, P., Baumann, P., Enea, R., Onaca, O., Palivan, C. & Meier, W. Polymeric vesicles: from drug carriers to nanoreactors and artificial organelles, *Accounts of chemical research*, 44 (2011) 1039-1049, doi:10.1021/ar200036k.

48 Jin, X., Zhu, D. D., Chen, B. Z., Ashfaq, M. & Guo, X. D. Insulin delivery systems combined with microneedle technology, *Adv Drug Deliv Rev*, 127 (2018) 119-137, doi:10.1016/j.addr.2018.03.011.

49 Jana, B. A. & Wadhvani, A. D. Microneedle - Future prospect for efficient drug delivery in diabetes

management, Indian journal of pharmacology, 51 (2019) 4–10, doi:10.4103/ijp.IJP_16_18.

50 Wu, Q., Wang, L., Yu, H., Wang, J. & Chen, Z. Organization of glucose-responsive systems and their
 51 properties, Chem Rev, 111 (2011) 7855–7875, doi:10.1021/cr200027j.

52 Kuivila, H. G., Keough, A. H. & Soboczenski, E. J. ARENEBORONATES FROM DIOLS AND POLYOLS¹, The Journal
 53 of Organic Chemistry, 19 (1954) 780–783, doi:10.1021/jo01370a013.

54 Ma, R. & Shi, L. Phenylboronic acid-based glucose-responsive polymeric nanoparticles: synthesis and
 55 applications in drug delivery, Polym. Chem., 5 (2014) 1503–1518, doi:10.1039/c3py01202f.

56 Shen, D., Yu, H., Wang, L., Khan, A., Haq, F., Chen, X., Huang, Q. & Teng, L. Recent progress in design
 57 and preparation of glucose-responsive insulin delivery systems, J Control Release, 321 (2020) 236–258,
 58 doi:10.1016/j.jconrel.2020.02.014.

59 Yang, H., Sun, X., Liu, G., Ma, R., Li, Z., An, Y. & Shi, L. Glucose-responsive complex micelles for
 60 self-regulated release of insulin under physiological conditions, Soft Matter, 9 (2013),
 61 doi:10.1039/c3sm51538a.

62 Wang, J., Ye, Y., Yu, J., Kahkoska, A. R., Zhang, X., Wang, C., Sun, W., Corder, R. D., Chen, Z., Khan,
 63 S. A., Buse, J. B. & Gu, Z. Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery, ACS Nano,
 64 12 (2018) 2466–2473, doi:10.1021/acsnano.7b08152.

65 Torchilin, V. P. Micellar nanocarriers: pharmaceutical perspectives, Pharm Res, 24 (2007) 1–16,
 66 doi:10.1007/s11095-006-9132-0.

67 Wang, J., Hu, X. & Xiang, D. Nanoparticle drug delivery systems: an excellent carrier for tumor peptide
 68 vaccines, Drug Deliv, 25 (2018) 1319–1327, doi:10.1080/10717544.2018.1477857.

69 Quijia Quezada, C., Azevedo, C. S., Charneau, S., Santana, J. M., Chorilli, M., Carneiro, M. B. & Bastos,
 70 I. M. D. Advances in nanocarriers as drug delivery systems in Chagas disease, Int J Nanomedicine, 14
 71 (2019) 6407–6424, doi:10.2147/IJN.S206109.

72 Edgar, J. Y. C. & Wang, H. Introduction for Design of Nanoparticle Based Drug Delivery Systems, Current
 73 pharmaceutical design, 23 (2017) 2108–2112, doi:10.2174/1381612822666161025154003.

74 Adams, M. L., Lavasanifar, A. & Kwon, G. S. Amphiphilic block copolymers for drug delivery, J Pharm
 75 Sci, 92 (2003) 1343–1355, doi:10.1002/jps.10397.

76 Khoei, S. & Rahmatollahzadeh, R. Synthesis and characterization of pH-responsive and folated
 77 nanoparticles based on self-assembled brush-like PLGA/PEG/AEMA copolymer with targeted cancer therapy
 78 properties: A comprehensive kinetic study, Eur J Med Chem, 50 (2012) 416–427,
 79 doi:10.1016/j.ejmech.2012.02.027.

80 Ashok, B., Rubinstein, I., Tsueshita, T. & Onyuksel, H. Effects of peptide molecular mass and PEG chain
 81 length on the vasoreactivity of VIP and PACAP(1–38) in pegylated phospholipid micelles, Peptides, 25
 82 (2004) 1253–1258, doi:10.1016/j.peptides.2004.05.013.

83 Schoch, R. L., Emilsson, G., Dahlin, A. B. & Lim, R. Y. H. Protein exclusion is preserved by temperature
 84 sensitive PEG brushes, Polymer, 132 (2017) 362–367, doi:10.1016/j.polymer.2017.10.063.

85 Akbarian, M., Ghasemi, Y., Uversky, V. N. & Yousefi, R. Chemical modifications of insulin: Finding
 86 a compromise between stability and pharmaceutical performance, Int J Pharm, 547 (2018) 450–468,
 87 doi:10.1016/j.ijpharm.2018.06.023.

88 Fineberg, S. E., Kawabata, T. T., Finco-Kent, D., Fountaine, R. J., Finch, G. L. & Krasner, A. S.
 89 Immunological responses to exogenous insulin, Endocr Rev, 28 (2007) 625–652, doi:10.1210/er.2007-0002.

90 Siposova, K., Pospiskova, K., Bednarikova, Z., Safarik, I., Safarikova, M., Kubovcikova, M., Kopcansky,
 91 P. & Gazova, Z. The molecular mass of dextran used to modify magnetite nanoparticles affects insulin
 92 amyloid aggregation, Journal of Magnetism and Magnetic Materials, 427 (2017) 48–53,
 93 doi:10.1016/j.jmmm.2016.10.083.

94 Lee, E. J., Lee, N. K. & Kim, I. S. Bioengineered protein-based nanocage for drug delivery, Adv Drug
 Deliv Rev, 106 (2016) 157–171, doi:10.1016/j.addr.2016.03.002.

Kapoor, D. N., Bhatia, A., Kaur, R., Sharma, R., Kaur, G. & Dhawan, S. PLGA: a unique polymer for drug
 delivery, Ther Deliv, 6 (2015) 41–58, doi:10.4155/tde.14.91.

Ding, D. & Zhu, Q. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics, *Mater Sci Eng C Mater Biol Appl*, 92 (2018) 1041–1060, doi:10.1016/j.msec.2017.12.036.

Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A. & Preat, V. PLGA-based nanoparticles: an overview of biomedical applications, *J Control Release*, 161 (2012) 505–522, doi:10.1016/j.jconrel.2012.01.043.

Kang, H. C., Lee, J. E. & Bae, Y. H. Nanoscaled buffering zone of charged (PLGA)_n-b-bPEI micelles in acidic microclimate for potential protein delivery application, *J Control Release*, 160 (2012) 440–450, doi:10.1016/j.jconrel.2012.02.024.

Zhang, Y., Lin, L., Liu, L., Liu, F., Maruyama, A., Tian, H. & Chen, X. Ionic-crosslinked polysaccharide/PEI/DNA nanoparticles for stabilized gene delivery, *Carbohydr Polym*, 201 (2018) 246–256, doi:10.1016/j.carbpol.2018.08.063.

Dong, X., Tian, H., Chen, L., Chen, J. & Chen, X. Biodegradable mPEG-b-P(MCC-g-OEI) copolymers for efficient gene delivery, *J Control Release*, 152 (2011) 135–142, doi:10.1016/j.jconrel.2011.03.025.

Huang, F. W., Wang, H. Y., Li, C., Wang, H. F., Sun, Y. X., Feng, J., Zhang, X. Z. & Zhuo, R. X. PEGylated PEI-based biodegradable polymers as non-viral gene vectors, *Acta Biomater*, 6 (2010) 4285–4295, doi:10.1016/j.actbio.2010.06.016.

Vader, P., Mol, E. A., Pasterkamp, G. & Schiffelers, R. M. Extracellular vesicles for drug delivery, *Adv Drug Deliv Rev*, 106 (2016) 148–156, doi:10.1016/j.addr.2016.02.006.

Ha, D., Yang, N. & Nadithe, V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges, *Acta pharmaceutica Sinica. B*, 6 (2016) 287–296, doi:10.1016/j.apsb.2016.02.001.

Surman, M., Drożdż, A., Stępień, E. & Przybyło, M. Extracellular Vesicles as Drug Delivery Systems – Methods of Production and Potential Therapeutic Applications, *Current pharmaceutical design*, 25 (2019) 132–154, doi:10.2174/1381612825666190306153318.

Kim, M. S., Haney, M. J., Zhao, Y., Yuan, D., Deygen, I., Klyachko, N. L., Kabanov, A. V. & Batrakova, E. V. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations, *Nanomedicine*, 14 (2018) 195–204, doi:10.1016/j.nano.2017.09.011.

Liu, Y., Du, J., Yan, M., Lau, M. Y., Hu, J., Han, H., Yang, O. O., Liang, S., Wei, W., Wang, H., Li, J., Zhu, X., Shi, L., Chen, W., Ji, C. & Lu, Y. Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication, *Nat Nanotechnol*, 8 (2013) 187–192, doi:10.1038/nnano.2012.264.

Traitel, T., Cohen, Y. & Kost, J. Characterization of glucose-sensitive insulin release systems in simulated in vivo conditions, *Biomaterials*, 21 (2000) 1679–1687, doi:10.1016/s0142-9612(00)00050-8.

Zhang, K. & Wu, X. Y. Modulated insulin permeation across a glucose-sensitive polymeric composite membrane, *J Control Release*, 80 (2002) 169–178, doi:10.1016/s0168-3659(02)00024-x.

Zhao, L., Xiao, C., Wang, L., Gai, G. & Ding, J. Glucose-sensitive polymer nanoparticles for self-regulated drug delivery, *Chem Commun (Camb)*, 52 (2016) 7633–7652, doi:10.1039/c6cc02202b.

Kochhar, J. S., Lim, W. X., Zou, S., Foo, W. Y., Pan, J. & Kang, L. Microneedle integrated transdermal patch for fast onset and sustained delivery of lidocaine, *Mol Pharm*, 10 (2013) 4272–4280, doi:10.1021/mp400359w.

Ito, Y., Nakahigashi, T., Yoshimoto, N., Ueda, Y., Hamasaki, N. & Takada, K. Transdermal insulin application system with dissolving microneedles, *Diabetes Technol Ther*, 14 (2012) 891–899, doi:10.1089/dia.2012.0096.

McAllister, D. V., Wang, P. M., Davis, S. P., Park, J. H., Canatella, P. J., Allen, M. G. & Prausnitz, M. R. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies, *Proc Natl Acad Sci U S A*, 100 (2003) 13755–13760, doi:10.1073/pnas.2331316100.

Zhang, Y., Yu, J., Kahkoska, A. R., Wang, J., Buse, J. B. & Gu, Z. Advances in transdermal insulin delivery, *Adv Drug Deliv Rev*, 139 (2019) 51–70, doi:10.1016/j.addr.2018.12.006.

Donnelly, R. F., Raj Singh, T. R. & Woolfson, A. D. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety, *Drug Deliv*, 17 (2010) 187–207, doi:10.3109/10717541003667798.

Nuxoll, E. E. & Siegel, R. A. BioMEMS devices for drug delivery, *IEEE Eng Med Biol Mag*, 28 (2009) 31–39, doi:10.1109/MEMB.2008.931014.

Napoli, A., Valentini, M., Tirelli, N., Muller, M. & Hubbell, J. A. Oxidation-responsive polymeric vesicles, *Nat Mater*, 3 (2004) 183–189, doi:10.1038/nmat1081.

Huo, M., Yuan, J., Tao, L. & Wei, Y. Redox-responsive polymers for drug delivery: from molecular design to applications, *Polym. Chem.*, 5 (2014) 1519–1528, doi:10.1039/c3py01192e.

Yu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., Ranson, D., Ligler, F. S., Buse, J. B. & Gu, Z. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery, *Proc Natl Acad Sci U S A*, 112 (2015) 8260–8265, doi:10.1073/pnas.1505405112.

Krohn, K. A., Link, J. M. & Mason, R. P. Molecular imaging of hypoxia, *J Nucl Med*, 49 Suppl 2 (2008) 129S–148S, doi:10.2967/jnumed.107.045914.

Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, *Adv Drug Deliv Rev*, 99 (2016) 28–51, doi:10.1016/j.addr.2015.09.012.

Haggag, Y. A., Faheem, A. M., Tambuwala, M. M., Osman, M. A., El-Gizawy, S. A., O'Hagan, B., Irwin, N. & McCarron, P. A. Effect of poly(ethylene glycol) content and formulation parameters on particulate properties and intraperitoneal delivery of insulin from PLGA nanoparticles prepared using the double-emulsion evaporation procedure, *Pharmaceutical development and technology*, 23 (2018) 370–381, doi:10.1080/10837450.2017.1295066.

Ramachandran, R., Paul, W. & Sharma, C. P. Synthesis and characterization of PEGylated calcium phosphate nanoparticles for oral insulin delivery, *Journal of biomedical materials research. Part B, Applied biomaterials*, 88 (2009) 41–48, doi:10.1002/jbm.b.31241.

Tomar, L., Tyagi, C., Kumar, M., Kumar, P., Singh, H., Choonara, Y. E. & Pillay, V. In vivo evaluation of a conjugated poly(lactide-ethylene glycol) nanoparticle depot formulation for prolonged insulin delivery in the diabetic rabbit model, *Int J Nanomedicine*, 8 (2013) 505–520, doi:10.2147/ijn.S38011.

Alavi, S. E., Cabot, P. J. & Moyle, P. M. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency, *Mol Pharm*, 16 (2019) 2278–2295, doi:10.1021/acs.molpharmaceut.9b00308.

Holst, J. J. & Gromada, J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans, *Am J Physiol Endocrinol Metab*, 287 (2004) E199–206, doi:10.1152/ajpendo.00545.2003.

Khan, R., Tomas, A. & Rutter, G. A. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide, *Peptides*, 125 (2020) 170201, doi:10.1016/j.peptides.2019.170201.

DeYoung, M. B., MacConell, L., Sarin, V., Trautmann, M. & Herbert, P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes, *Diabetes Technol Ther*, 13 (2011) 1145–1154, doi:10.1089/dia.2011.0050.

Cullis, P. R. & Hope, M. J. Lipid Nanoparticle Systems for Enabling Gene Therapies, *Mol Ther*, 25 (2017) 1467–1475, doi:10.1016/j.ymthe.2017.03.013.

Wang, X., Niu, D., Hu, C. & Li, P. Polyethyleneimine-Based Nanocarriers for Gene Delivery, *Current pharmaceutical design*, 21 (2015) 6140–6156, doi:10.2174/1381612821666151027152907.

Pandey, A. P. & Sawant, K. K. Polyethylenimine: A versatile, multifunctional non-viral vector for nucleic acid delivery, *Mater Sci Eng C Mater Biol Appl*, 68 (2016) 904–918, doi:10.1016/j.msec.2016.07.066.

Lungwitz, U., Breunig, M., Blunk, T. & Gopferich, A. Polyethylenimine-based non-viral gene delivery systems, *Eur J Pharm Biopharm*, 60 (2005) 247–266, doi:10.1016/j.ejpb.2004.11.011.

893 105 Ziaee, A., Albadarin, A. B., Padrela, L., Femmer, T., O'Reilly, E. & Walker, G. Spray drying of
894 pharmaceuticals and biopharmaceuticals: Critical parameters and experimental process optimization
895 approaches, *Eur J Pharm Sci*, 127 (2019) 300–318, doi:10.1016/j.ejps.2018.10.026.

896 106 Arpagaus, C., Collenberg, A., Rutti, D., Assadpour, E. & Jafari, S. M. Nano spray drying for
897 encapsulation of pharmaceuticals, *Int J Pharm*, 546 (2018) 194–214, doi:10.1016/j.ijpharm.2018.05.037.

898 107 Wanning, S., Suverkrup, R. & Lamprecht, A. Pharmaceutical spray freeze drying, *Int J Pharm*, 488 (2015)
899 136–153, doi:10.1016/j.ijpharm.2015.04.053.

900 108 Grigoras, A. G. Polymer–lipid hybrid systems used as carriers for insulin delivery, *Nanomedicine*, 13
901 (2017) 2425–2437, doi:10.1016/j.nano.2017.08.005.

902 109 Dreiss, C. A. Hydrogel design strategies for drug delivery, *Current Opinion in Colloid & Interface*
903 *Science*, 48 (2020) 1–17, doi:10.1016/j.cocis.2020.02.001.

904 110 Li, K., Yu, L., Liu, X., Chen, C., Chen, Q. & Ding, J. A long-acting formulation of a polypeptide drug
905 exenatide in treatment of diabetes using an injectable block copolymer hydrogel, *Biomaterials*, 34 (2013)
906 2834–2842, doi:10.1016/j.biomaterials.2013.01.013.

907 111 Chen, Y., Li, Y., Shen, W., Li, K., Yu, L., Chen, Q. & Ding, J. Controlled release of liraglutide using
908 thermogelling polymers in treatment of diabetes, *Sci Rep*, 6 (2016) 31593, doi:10.1038/srep31593.

909 112 Choi, S., Baudys, M. & Kim, S. W. Control of blood glucose by novel GLP-1 delivery using biodegradable
910 triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats, *Pharm Res*, 21 (2004) 827–831,
911 doi:10.1023/b:pham.0000026435.27086.94.

912 113 Yu, L., Li, K., Liu, X., Chen, C., Bao, Y., Ci, T., Chen, Q. & Ding, J. In vitro and in vivo evaluation
913 of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel,
914 *J Pharm Sci*, 102 (2013) 4140–4149, doi:10.1002/jps.23735.

915 114 Huynh, D. P., Im, G. J., Chae, S. Y., Lee, K. C. & Lee, D. S. Controlled release of insulin from
916 pH/temperature-sensitive injectable pentablock copolymer hydrogel, *J Control Release*, 137 (2009) 20–24,
917 doi:10.1016/j.jconrel.2009.02.021.

918 115 Oak, M. & Singh, J. Chitosan-zinc-insulin complex incorporated thermosensitive polymer for controlled
919 delivery of basal insulin in vivo, *J Control Release*, 163 (2012) 145–153,
920 doi:10.1016/j.jconrel.2012.07.035.

921 116 Wang, Q., Zuo, Z., Cheung, C. K. C. & Leung, S. S. Y. Updates on thermosensitive hydrogel for nasal,
922 ocular and cutaneous delivery, *Int J Pharm*, 559 (2019) 86–101, doi:10.1016/j.ijpharm.2019.01.030.

923 117 Qureshi, D., Nayak, S. K., Maji, S., Anis, A., Kim, D. & Pal, K. Environment sensitive hydrogels for
924 drug delivery applications, *European Polymer Journal*, 120 (2019),
925 doi:10.1016/j.eurpolymj.2019.109220.

926 118 Norouzi, M., Nazari, B. & Miller, D. W. Injectable hydrogel-based drug delivery systems for local cancer
927 therapy, *Drug Discov Today*, 21 (2016) 1835–1849, doi:10.1016/j.drudis.2016.07.006.

928 119 Dutta, K., Das, R., Ling, J., Monibas, R. M., Carballo-Jane, E., Kekec, A., Feng, D. D., Lin, S., Mu,
929 J., Saklatvala, R., Thayumanavan, S. & Liang, Y. In Situ Forming Injectable Thermoresponsive Hydrogels
930 for Controlled Delivery of Biomacromolecules, *ACS omega*, 5 (2020) 17531–17542,
931 doi:10.1021/acsomega.0c02009.

932 120 Vilsboll, T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus,
933 *Expert Opin Investig Drugs*, 16 (2007) 231–237, doi:10.1517/13543784.16.2.231.

934 121 Ryan, G. J., Foster, K. T. & Jobe, L. J. Review of the therapeutic uses of liraglutide, *Clin Ther*,
935 33 (2011) 793–811, doi:10.1016/j.clinthera.2011.06.004.

936 122 Muller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A.,
937 Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A.,
938 Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., Seeley, R. J., Stemmer,
939 K., Tang-Christensen, M., Woods, S. C., DiMarchi, R. D. & Tschop, M. H. Glucagon-like peptide 1 (GLP-1),
940 *Mol Metab*, 30 (2019) 72–130, doi:10.1016/j.molmet.2019.09.010.

941 123 Su, K., Yi, B., Yao, B. Q., Xia, T., Yang, Y. F., Zhang, Z. H. & Chen, C. Liraglutide attenuates renal

tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis, *Pharmacol Res*, 156 (2020) 104778, doi:10.1016/j.phrs.2020.104778.

124 Vilsboll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. H., Kolendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le-Thi, T. & Madsbad, S. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus, *Diabet Med*, 25 (2008) 152-156, doi:10.1111/j.1464-5491.2007.02333.x.

125 Russell-Jones, D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue, *Mol Cell Endocrinol*, 297 (2009) 137-140, doi:10.1016/j.mce.2008.11.018.

126 Newsome, J. S. Lixisenatide: A New Option for Managing Type 2 Diabetes, *Journal of Pharmacy Technology*, 33 (2017) 195-203, doi:10.1177/8755122517711958.

127 Varin, E. M., McLean, B. A. & Lovshin, J. A. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials, *Can J Diabetes*, 44 (2020) 68-77, doi:10.1016/j.jcjd.2019.08.011.

128 Meng, L., Li, X. Y., Shen, L. & Ji, H. F. Type 2 Diabetes Mellitus Drugs for Alzheimer's Disease: Current Evidence and Therapeutic Opportunities, *Trends Mol Med*, 26 (2020) 597-614, doi:10.1016/j.molmed.2020.02.002.

129 Song, C.-C., Ji, R., Du, F.-S. & Li, Z.-C. Oxidation-Responsive Poly(amino ester)s Containing Arylboronic Ester and Self-Immolative Motif: Synthesis and Degradation Study, *Macromolecules*, 46 (2013) 8416-8425, doi:10.1021/ma401656t.

130 Sorlier, P., Denuziere, A., Viton, C. & Domard, A. Relation between the degree of acetylation and the electrostatic properties of chitin and chitosan, *Biomacromolecules*, 2 (2001) 765-772, doi:10.1021/bm015531+.

131 Gong, C., Qi, T., Wei, X., Qu, Y., Wu, Q., Luo, F. & Qian, Z. Thermosensitive Polymeric Hydrogels As Drug Delivery Systems, *Current Medicinal Chemistry*, 20 (2013) 79-94.

132 Almeida, A., Araujo, M., Novoa-Carballal, R., Andrade, F., Goncalves, H., Reis, R. L., Lucio, M., Schwartz, S., Jr. & Sarmiento, B. Novel amphiphilic chitosan micelles as carriers for hydrophobic anticancer drugs, *Mater Sci Eng C Mater Biol Appl*, 112 (2020) 110920, doi:10.1016/j.msec.2020.110920.

133 Zhang, C., Ding, Y., Yu, L. L. & Ping, Q. Polymeric micelle systems of hydroxycamptothecin based on amphiphilic N-alkyl-N-trimethyl chitosan derivatives, *Colloids Surf B Biointerfaces*, 55 (2007) 192-199, doi:10.1016/j.colsurfb.2006.11.031.

134 Zhou, Y. Y., Du, Y. Z., Wang, L., Yuan, H., Zhou, J. P. & Hu, F. Q. Preparation and pharmacodynamics of stearic acid and poly (lactic-co-glycolic acid) grafted chitosan oligosaccharide micelles for 10-hydroxycamptothecin, *Int J Pharm*, 393 (2010) 143-151, doi:10.1016/j.ijpharm.2010.04.025.

135 Zhang, M., Li, X. H., Gong, Y. D., Zhao, N. M. & Zhang, X. F. Properties and biocompatibility of chitosan films modified by blending with PEG, *Biomaterials*, 23 (2002) 2641-2648, doi:10.1016/s0142-9612(01)00403-3.

136 Sugimoto, M., Morimoto, M., Sashiwa, H., Saimoto, H. & Shigemasa, Y. Preparation and characterization of water-soluble chitin and chitosan derivatives, *Carbohydrate Polymers*, 36 (1998) 49-59, doi:10.1016/S0144-8617(97)00235-X.

137 Prego, C., Torres, D., Fernandez-Megia, E., Novoa-Carballal, R., Quinoa, E. & Alonso, M. J. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree, *J Control Release*, 111 (2006) 299-308, doi:10.1016/j.jconrel.2005.12.015.